Searchable abstracts of presentations at key conferences in endocrinology

ea0029p59 | Adrenal cortex | ICEECE2012

The effects of the acute administration of alprazolam, a benzodiazepine, in patients with subclinical Cushing’s syndrome

Berardelli R. , Karamouzis I. , Marinazzo E. , Picu A. , D'Angelo V. , Ghigo E. , Arvat E. , Giordano R.

Subclinical Cushing’s syndrome (SCS) is a status of altered hypothalamo-pituitary-adrenal (HPA)-axis secretion in the absence of the classical signs or symptoms of overt cortisol excess. Among the various tests used for the diagnosis of SCS, the 1-mg dexamethasone test (DST) is the most used. Alprazolam (ALP), a benzodiazepine activating GABAergic receptors, possesses clear centrally-mediated inhibitory effects on ACTH and cortisol secretion in normal subjects, while it d...

ea0020p575 | Neuroendocrinology, Pituitary and Behaviour | ECE2009

Effect of prolonged treatment with potassium canrenoate, a MR antagonist, on basal and stimulated hypothalamus–pituitary–adrenal (HPA) axis in humans

Berardelli Rita , Marinazzo Elisa , Prats Elisa , Picu Andreea , Giordano Roberta , Ghigo Ezio , Arvat Emanuela

HPA is negatively regulated by glucocorticoid feed-back at hypothalamic, pituitary and hippocampal level by glucocorticoid (GR) and mineralcorticoid (MR) receptors. MR antagonists impair HPA rhythm after acute administration. The aim of this study was to verify HPA activity and glico-insulinemic profile both basally and after acute administration of potassium canrenoate (CAN), before and after chronic treatment. We evaluated ACTH, cortisol (F) and dehydroepiandosterone (DHEA) ...

ea0016p30 | Adrenal | ECE2008

Hormonal, metabolic and bone evaluation in a series of adrenal incidentalomas

Bonelli Lorenza , Giordano Roberta , Balbo Marcella , Berardelli Rita , Marinazzo Elisa , Ghigo Ezio , Arvat Emanuela

Clinically silent adrenal masses discovered by abdominal imaging procedures performed for non-adrenal disorders, i.e. adrenal incidentalomas, have become a common finding in clinical practice and they represent a clinical concern because of the risk not only of malignancy but also of subclinical hormonal hypersecretion (SCS) that represents a new risk factor for cardiovascular diseases and/or osteoporosis. We studied 73 patients (39F, 34M; mean±S.E.M.: 61.6...

ea0016p50 | Adrenal | ECE2008

Metabolic and cardiovascular profile in adult patients with addison's disease under conventional glucocorticoid replacement therapy

Giordano Roberta , Falorni Alberto , Balbo Marcella , Marzotti Stefania , Romagnoli Serena , Marinazzo Elisa , Ghigo Ezio , Arvat Emanuela

Object: In Addison’s disease hydrocortisone or cortisone have so far been used at doses of 30–37.5 mg/day, respectively, though several studies showed that cortisol normal production is about 5.7 mg/m2 (20–25 mg/day of hydrocortisone or cortisone, respectively). Differently from secondary hypoadrenalism, scanty data exist in patients with Addison’s disease on role of conventional glucocorticoid replacement and metabolic and cardiovascular outcome...

ea0014p569 | (1) | ECE2007

Cortisol and dexamethasone exert different negative feedback action in humans

Giordano Roberta , Berardelli Rita , Picu Andreea , Balbo Marcella , Bonelli Lorenza , Barberis Anna , Ghigo Ezio , Arvat Emanuela

HPA response to glucocorticoids (GCs) feedback is usually tested by dexamethasone (DEX), a synthetic GC; it poorly crosses BBB and preferentially activates pituitaric glucocorticoid receptor (GR), with a binding potency to GR 7 fold higher and an anti-inflammatory potency about 35 fold higher than cortisol. Cortisol, which easily penetrates into CNS, could better evaluate the GC feedback by acting also at supra-pituitary level. We studied the effects of 150 min infusion of hyd...

ea0099ep311 | Adrenal and Cardiovascular Endocrinology | ECE2024

Impact of 10 years of conventional steroids vs dual-release hydrocortisone on metabolic, cardiovascular, and bone outcomes in treatment-naïve patients with adrenal insufficiency

Guarnotta Valentina , Di Stefano Claudia , Tomasello Laura , Pizzolanti Giuseppe , Arnaldi Giorgio , Giordano Carla

Patients with adrenal insufficiency show higher mortality than in the general population, mainly due to non-physiological daily glucocorticoid overexposure and to inadequate cortisol exposure during stress-related events and illness. The aim of the current study is to compare the impact of 10 years of conventional glucocorticoid (GC) replacement treatment and dual-release hydrocortisone (DR-HC), on anthropometric, metabolic, cardiovascular and bone outcomes in treatment-na&#23...

ea0081rc14.8 | Rapid Communications 14: Late Breaking | ECE2022

Insulin resistance prevents SHBG increase after VLCKD in non-diabetic obese male subjects

Annamaria Genchi Valentina , Cignarelli Angelo , Di Leo Simona , Giordano Fiorella , Conte Eleonora , Perrini Sebastio , Natalicchio Annalisa , Laviola Luigi , Giorgino Francesco

Hepatocytes are both insulin sensitive and the primary site for synthesis of SHBG. Thus, it is possible that a condition of hepatic insulin resistance may impair hepatic synthesis of SHBG. In this study, we assessed SHBG circulating levels after 30 days of a very low-calorie ketogenic diet (VLCKD) based on high-biological value protein preparations diet (ISOMED) and natural food in a cohort of insulin-resistant obese male subjects. Moreover, we investigated the effects of expo...

ea0029p844 | Endocrine tumours and neoplasia | ICEECE2012

Establishment of a Multidisciplinary Tumor Board for Patients with Neuroendocrine Neoplasms

Bianchi A. , Iacovazzo D. , Plastino F. , Lugli F. , Pontecorvi A. , Doglietto G. , Giordano A. , Barone C. , De Marinis L. , Rindi G.

Introduction: Neuroendocrine neoplasms are rare and multiform requiring a multidisciplinary approach. We report the experience of a Neuroendocrine tumor board (TB) established at our University Hospital.Aims: The aim is to share clinical and diagnostic data for best decision-making according to the existing ENETS guidelines.Materials and methods: According to the indications for ENETS Centers of Excellence, meetings with experts in...

ea0029p1143 | Neuroendocrinology | ICEECE2012

Basal and stimulated GH secretion in active cushing’s syndrome and 2 years after remission

Picu A. , D'Angelo V. , Karamouzis I. , Berardelli R. , Marinazzo E. , Fussotto B. , Zichi C. , Giordano R. , Ghigo E. , Arvat E.

Impaired GH secretion occurs in Cushing’s syndrome (CS), reflecting hypothalamic and pituitary alterations, without IGF-I impairment. Obesity is known to blunt GH release, leading to BMI-related tests for GHD. Evaluation of GH in CS after remission is difficult, due to chronic previous hypercortisolism and persistent overweight. Aim of this study was to evaluate in 22 patients with Cushing’s syndrome (16 Cushing disease, CD, 6 adrenal adenomas, CS) GH response to GHR...

ea0029p1782 | Thyroid cancer | ICEECE2012

Functional and molecular characterization of cancer stem cells in anaplastic thyroid carcinoma

Carina V. , Zito G. , Pizzolanti G. , Richiusa P. , Tomasello L. , Pitrone M. , Baiamonte C. , Guarnotta V. , Giordano C.

Anaplastic Thyroid Carcinoma (ATC) is the most aggressive thyroid gland malignancy characterized by undifferentiated morphology. It has been suggested that cancer stem cells (CSCs) might play a central role in ATC. Previously on the basis of CD133 positivity, our group suggested that CD133+ cancer stem cells (CSCs) might play a central role in ATC. Here we analyzed a panel of different stem cell markers in order to identify a peculiar CSC pattern in ATC....